Sumanta K. Pal, MD

Sumanta Kumar Pal, MD, FASCO, provides advice for community oncologists, and the Oncology Brothers review key points from the discussion.

Focusing on advanced kidney cancer, medical oncologists offer clinical perspectives on treatment in the second line and beyond.

The Oncology Brothers and Sumanta Kumar Pal, MD, FASCO, offer comprehensive insights on the treatment of patients with metastatic kidney cancer.

Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney cancer following surgery.

Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.

This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

Adrenocortical carcinoma is a rare disease, with an annual incidence rate ranging from 0.5 to 2.0 cases per million individuals.